These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19427270)

  • 1. Ascorbic acid for treatment of CMT1A: the jury is still out.
    Shy M
    Lancet Neurol; 2009 Jun; 8(6):505-7. PubMed ID: 19427270
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?
    Pareyson D; Solari A
    Lancet Neurol; 2009 Dec; 8(12):1075-7. PubMed ID: 19818689
    [No Abstract]   [Full Text] [Related]  

  • 4. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ascorbic acid: a first generation drug for Charcot-Marie-Tooth disease].
    Fontès M
    Med Sci (Paris); 2004 Oct; 20(10):843-4. PubMed ID: 15461953
    [No Abstract]   [Full Text] [Related]  

  • 6. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.
    Toth C
    Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid for treatment in CMT1A: what's next?
    de Visser M; Verhamme C
    Lancet Neurol; 2011 Apr; 10(4):291-3. PubMed ID: 21393064
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ascorbic Acid and Charcot-Marie-Tooth Disease].
    Noto Y
    Brain Nerve; 2015 Oct; 67(10):1241-6. PubMed ID: 26450076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.
    Pareyson D; Reilly MM; Schenone A; Fabrizi GM; Cavallaro T; Santoro L; Vita G; Quattrone A; Padua L; Gemignani F; Visioli F; Laurà M; Radice D; Calabrese D; Hughes RA; Solari A; ;
    Lancet Neurol; 2011 Apr; 10(4):320-8. PubMed ID: 21393063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.
    Reilly MM; de Jonghe P; Pareyson D
    Neuromuscul Disord; 2006 Jun; 16(6):396-402. PubMed ID: 16684603
    [No Abstract]   [Full Text] [Related]  

  • 11. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment.
    Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D
    Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27].
    Pareyson D; Schenone A; Fabrizi GM; Santoro L; Padua L; Quattrone A; Vita G; Gemignani F; Visioli F; Solari A;
    Pharmacol Res; 2006 Dec; 54(6):436-41. PubMed ID: 17029975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
    Passage E; Norreel JC; Noack-Fraissignes P; Sanguedolce V; Pizant J; Thirion X; Robaglia-Schlupp A; Pellissier JF; Fontés M
    Nat Med; 2004 Apr; 10(4):396-401. PubMed ID: 15034573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in children with CMT type 1A.
    Ramchandren S; Shy ME; Finkel RS
    Lancet Neurol; 2009 Oct; 8(10):880-1; author reply 881. PubMed ID: 19747650
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.
    Verhamme C; de Haan RJ; Vermeulen M; Baas F; de Visser M; van Schaik IN
    BMC Med; 2009 Nov; 7():70. PubMed ID: 19909499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acid.
    Burns J; Ouvrier RA; Yiu EM; Ryan MM
    J Peripher Nerv Syst; 2011 Sep; 16(3):272-4. PubMed ID: 22003943
    [No Abstract]   [Full Text] [Related]  

  • 17. Ascorbic acid and sodium-dependent vitamin C transporters in the peripheral nervous system: from basic science to clinical trials.
    Gess B; Röhr D; Young P
    Antioxid Redox Signal; 2013 Dec; 19(17):2105-14. PubMed ID: 23642070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whither hope for pharmacological treatment of Charcot-Marie-Tooth disease type 1A?
    Patel PI; Pleasure D
    JAMA Neurol; 2013 Aug; 70(8):969-71. PubMed ID: 23797977
    [No Abstract]   [Full Text] [Related]  

  • 19. New treatments for denervating diseases.
    Pleasure D
    J Child Neurol; 2005 Mar; 20(3):258-62. PubMed ID: 15832625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Charcot-Marie-Tooth disease].
    Lee YC; Chang MH; Lin KP
    Acta Neurol Taiwan; 2008 Sep; 17(3):203-13. PubMed ID: 18975529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.